Clinical Trial Update: A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial update on subcutaneous nivolumab plus relatlimab fixed-dose combination for previously untreated metastatic or unresectable melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING